What is Lila Sciences?
Headquartered in Cambridge, Massachusetts, Lila Sciences is a venture-backed enterprise founded in 2023 that is redefining the speed and scale of scientific experimentation. The company's core innovation, the AI Science Factory (AISF), functions as an autonomous system capable of designing, conducting, and iterating on experiments without human intervention. This platform has already demonstrated significant utility in the discovery of novel antibodies, genetic medicine constructs, and advanced materials for green energy. Led by CEO Geoffrey von Maltzahn and Chief Scientist George Church, the firm is currently scaling its operations with planned expansions into San Francisco and London, aiming to establish a global footprint for its high-throughput scientific engine.
How much funding has Lila Sciences raised?
Lila Sciences has raised a total of $437M across 3 funding rounds:
Angel/Seed
$200M
Series A
$235M
Stock/Share Issuance
$2M
Angel/Seed (2025): $200M with participation from Ark Venture Fund, Blue Horizon Advisors, Altitude Life Science Ventures, March Capital, Flagship Pioneering, Modi Ventures, and General Catalyst
Series A (2025): $235M led by Collective Global and Braidwell
Stock/Share Issuance (2026): $2M, investors not publicly disclosed
Key Investors in Lila Sciences
Braidwell
Braidwell provides flexible capital and strategic partnership to organizations transforming human health, operating across all stages of development and capital structures.
Collective Global
Collective Global is an investment collective formed by leading allocators that partners with elite venture managers to provide strategic funding solutions for growth-stage companies.
General Catalyst
General Catalyst is a prominent venture capital firm that supports transformational businesses across multiple sectors, providing operational expertise and strategic guidance to help companies achieve substantial scale.
What's next for Lila Sciences?
With the recent influx of capital, Lila Sciences is poised to transition from its initial development phase into a period of rapid operational scaling. The company intends to leverage these resources to enhance the capabilities of its AISF platform, broadening its application across diverse verticals including carbon capture and precision medicine. As the firm continues to iterate on its autonomous lab infrastructure, the focus will shift toward commercializing its discovery pipeline and solidifying its position as a mission-critical partner for global life science and materials enterprises. The strategic backing from top-tier investors provides the necessary runway to maintain its competitive edge in the burgeoning tech-bio sector.
See full Lila Sciences company page
